Its product portfolio comprises MCT-125, a Phase II therapeutic candidate for the treatment of primary multiple sclerosis-related fatigue; MCT-465, a preclinical synthetic double-stranded RNA ...
GlobeStar Therapeutics Corporation, a clinical stage pharmaceutical company, focuses on developing a patented formulation of drugs for the treatment of multiple sclerosis and other ...
Shares of TG Therapeutics rose after the company raised its guidance on better-than-expected sales of its multiple sclerosis drug. Shares were up 7.7% Tuesday to $29.79. The stock is about 18% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback